Nitric oxide (NO) is an important vasodilator with a well-established role in cardiovascular
homeostasis. While mediator is synthesized from L-arginine by neuronal, endothelial, and …

The incidence of type 2 diabetes (T2D) and its costs to the health care system continue to
rise. Despite the availability of at least 10 drug classes for the treatment of T2D, metformin …

Clinical genetic testing began over 30 years ago with the availability of mutation detection
for sickle cell disease diagnosis. Since then, the field has dramatically transformed to …

Statins are a cornerstone of the pharmacologic treatment and prevention of atherosclerotic
cardiovascular disease. Atherosclerotic disease is a predominant cause of mortality and …

About half of people who take antidepressants do not respond and many experience
adverse effects. These detrimental outcomes are in part a result of the impact of an …

Nitric oxide (NO) is a vasoactive substance synthesized from l-arginine by neuronal (NOS1),
endothelial (NOS3), and inducible (NOS2) nitric oxide synthases. NOS3 is the most …

Health disparities are well-documented among different racial and ethnic minority groups in
the United States. Filipino Americans (FAs) are the third-largest Asian-American group in the …

Pharmacogenomics and personalized medicine interventions hold promise to optimize drug
treatment modalities and hence, improve the quality of life of the patients by minimizing the …

The progressing discovery of genetic variants associated with drug-related adverse events
has raised expectations for pharmacogenetic tests to improve drug efficacy and safety. To …

The implementation of pharmacogenomics (PGx) has come a long way since the dawn of
utilizing pharmacogenomic data in clinical patient care. However, the potential benefits of …